ProPhase Labs's net income is $-24M, below the Healthcare sector average of $16B.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2026
Trailing 12 months ending Mar 2026
Loading...
Loading...
ProPhase Labs (PRPH) currently reports a net income of $-24M as of March 2026. That compares with $-43M in the prior-year period — up 44.2% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore ProPhase Labs's net income history and peer comparisons.
ProPhase Labs's net income increased from $-43M to $-24M — a 44.2% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
ProPhase Labs's net income of $-24M is lower than the Healthcare sector average of $16B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
ProPhase Labs reported $-24M in net income as of March 2026. That compares with $-43M in the prior-year period — up 44.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current net income of $-24M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for ProPhase Labs, and consider following PRPH for alerts when major investors trade the stock.